Association between serum homocysteine concentration with coronary artery disease in Iranian patients
Ahmad Mirdamadi(1), Hamid Farzamnia(2), Pooyan Varzandeh(3), Naser Almasi(4), Mahfar Arasteh(5)*

Abstract

BACKGROUND: The role of novel biomarkers like homocysteine as a risk factor of coronary artery disease (CAD) is being increasingly recognized. Since there is a marked geographical variation in plasma homocystein concentration and because of importance of hyperhomocysteinemia as a CAD risk factor and due to the paucity of studies in Iran evaluating this risk factor in our population, we evaluated the association between plasma total homocysteine (tHcy) concentration and CAD risk in Iranian population.

METHODS: In a case-control study, we compared the level of tHcy of forty five patients of angiographically proven CAD with forty five subjects without CAD as control group matched for age and gender. The patients with diabetes, hypertension, thyroid dysfunction, chronic renal failure, hyperlipidemia and obesity and other conventional CAD risk factors were excluded from the study. Plasma tHcy was measured using immunoturbidimetry. The results were compared between groups using student t test.

RESULTS: CAD patients had significantly higher mean plasma tHcy than control group (17.1±5.3 versus 14.2±3.8, P= 0.004).

CONCLUSION: This study denoted that high plasma homocysteine concentration was associated to CAD risk in Iranian people.

Keywords: Coronary Artery Disease, Homocysteine.

ARYA Atherosclerosis 2011; 7(2): 63-67.

Date of submission: 6 May 2011, Date of acceptance: 12 Jul 2011

Introduction

Coronary artery disease is the leading cause of death and disability worldwide. Although Most of coronary artery disease patients have at least one of cardiovascular risk factors, 20% of patients with coronary artery disease have no conventional risk factors.1 The role of novel biomarkers including homocysteine in atherothrombotic vascular disease and prediction of risk of CAD is being increasingly recognized.2-6 Many studies found homocysteine level to be associated to atherosclerotic disease including CAD.7,10 Another investigation showed this risk rises with increasing level of plasma homocysteine and has no threshold.11 Hyperhomocysteinemia increases the risk of coronary artery disease by increased thrombosis, adverse effects on endothelial function, promoting thickening of the intima and oxidative damage of low density lipoprotein.12 The hyperhomocysteinemia was reported in 40% of patients with vascular disease8 and lowering plasma homocysteine level would reduce the risk of CAD by 16%.13 Additionally, some studies showed hyperhomocysteinemia may have prognostic value in mortality of patients with CAD.14 The role of elevated homocysteine level in CAD seems to be complex and further studies are needed to clarify the relationship of homocysteine and atherosclerosis. Moreover, some studies demonstrated that there is difference in prevalence and importance of homocysteine in CAD in different ethnic groups.15,16 There are a few studies in Iran evaluating the extent of impact of hyperhomocysteinemia on CAD risk in our population.17,18 The aim of the present study was to determine the relationship between...
Hyperhomocysteinemia and CAD in Iranian population.

**Materials and Methods**

The consecutive patients admitted to the Department of Angiography of Noor, Sina and Chamran hospitals of Esfahan for evaluation of CAD and undergone coronary angiography in the year of 2010 were included in the study. Based on angiography results, the patients were divided into two groups. Those who had stenosis of ≥75% in at least one of their major coronary arteries were considered as CAD or case group and other patients served as non-CAD or control group. The patients with diabetes, hypertension, thyroid dysfunction, chronic renal failure, hyperlipidemia and obesity and other CAD risk factors were excluded from the study. Forty-five patients with CAD were compared with forty-five subjects that had normal coronary arteries in angiography, matched for age and gender. The level of homocysteine was measured in two groups using immunoturbidimetry method. Samples for plasma tHcy were placed on ice, serum was separated within 1 hour and was stored at -70°C. Statistical analyses were carried out using SPSS 13. Homocysteine and continuous variables reported as mean ± SD, were compared using student t test. Comparison of frequencies was carried out using X² test or Fishers extract test as appropriate.

**Results**

Table 1 shows demographic characteristics of cases and controls. Mean age of participants in CAD and control groups were 50.8±5.2 and 47.7±8.3 years, respectively. CAD group had significantly higher level of homocysteine than those in the control group (17.1±5.3 versus 14.2±3.8 micromol/lit, respectively, P= 0.004). Totally, 16 (35.6%) vs. 4 (8.9%) subjects in control and CAD groups, respectively, suffered from stable angina. Prevalence of MI and unstable angina were significantly higher in CAD group (P = 0.001). Homocysteine levels were higher in men than in women (16.7±5.2 and 14.3±3.9 micromol/lit, respectively, P=0.019).

**Discussion**

In spite of multiple studies, the role of hyperhomocysteinemia as a risk factor of CAD is still disputed. Boushey et al. estimated that 10% of general population CAD risk is attributed to homocysteine. They found that a 5-mumol/lit increment in tHcy increases odds ratio for CAD as great as 1.6 for men and 1.8 for women. Nygard et al. found a strong association between elevated tHcy concentration and overall mortality in CAD patients. Consistent graded relationship between plasma tHcy concentration and CAD risk were found both in the British BUPA cohort and Tromso study.

Although almost all retrospective and most of prospective studies have confirmed the role of homocysteine as an independent risk factor of CAD, some studies suggest that hyperhomocysteinemia may be secondary to preclinical vascular disease. Additionally, several studies demonstrated that hyperhomocysteinemia is a causal risk factor for CAD. In other words, elevated level of homocysteine interacts with other conventional risk factors and in combination with these factors increases the risk of atherothrombotic vascular disease. A case-control study demonstrated that hyperhomocysteinemia had more effect on CAD risk in hypertensive patients, smokers and patients with hypercholesterolemia than in normal population. Donner et al. excluded the patients with other risk profiles from their study and concluded that

**Table 1. Demographic and clinical characteristics of study population**

| Risk factors                              | Coronary artery disease (CAD) | Controls       | P value |
|-------------------------------------------|-------------------------------|----------------|---------|
| Sex (male/female)                         | 30/45 (66.7%)                 | 22/45 (48.9%)  | 0.09    |
| Age (years)                               | 50.8±5.2                      | 47.7±8.3       | 0.06    |
| tHcy (micromol/lit)                       |                               |                |         |
| Men                                       | 18±5.9                        | 14.9±3.4       | 0.27    |
| Women                                     | 15.3±3.5                      | 13.6±4.1       | 0.11    |
| Total                                     | 17.1±5.3                      | 14.2±3.8       | 0.004   |
| Myocardial infarction (mean ± SD)         | 5 (11.1%)                     | 0 (0%)         | 0.001   |
| Stable Angina (mean ± SD)                 | 4 (8.9%)                      | 16 (35.6%)     | 0.001   |
| Unstable Angina (mean ± SD)               | 36 (80%)                      | 29 (64.4%)     | 0.001   |

SD; Standard deviation
hyperhomocysteinemia is not associated to premature CAD in patients without diabetes, hypertension, hyperlipidemia. A metaanalysis demonstrated homocysteine level was less strongly associated to ischemic heart disease and stroke in general population than has been reported. The American multiple risk factor intervention trial (MRFIT) and Finnish North Karelia project failed to find any association between hyperhomocysteinemia and CAD. On the contrary, in Framingham heart study a strong association between elevated level of homocysteine and CAD even after adjustment of other coronary risk factors was found. A prospective study carried out by Whincup had the same result. In the present investigation, we excluded subjects with other cardiovascular risk factors from our study. We found a strong association between plasma tHcy and CAD independent of other conventional CAD risk factors.

Differences in design, statistical approach and power may partly explain variations in results of different studies but other causes of erratic results may be nutritional and large interethnic genetic variations.

The major determinants of plasma homocysteine level are B vitamins and folate intake and genetic factors. Methylene tetrahydrofolate reductase (MTHFR) is an enzyme required for conversion of homocysteine to methionine. Polymorphism of MTHFR in individual with the TT genotype leads to reduced enzyme activity and increased homocysteine concentration. The frequency of polymorphism of MTHFR varies in different racial and ethnic groups. Investigations showed that almost 12% of Asian population is homozygote for T allele (T/T) and up to 50% of them are heterozygote for it (C/T). Moreover, studies of Japanese population showed a significant association between TT genotype and CAD risk. It is denoted that in addition to geographical variation in dietary folate intake, geographical variation in the frequency of genetic polymorphism may be important in impact of hyperhomocysteinemia on CAD risk. There are a few studies evaluating relationship between plasma tHcy and CAD in Middle East especially in Iran and adjustment of other cardiovascular risk factors was not carried out by any of these studies. One study performed on samples of male adults in the south west of Iran found significant association between high plasma homocysteine and CAD. Kazemi et al. study showed the patients with abnormal angiography reports had higher levels of homocysteine compared with the patients with normal angiography reports and it was concluded that the increased level of homocysteine is an independent risk factor of CAD. In contrast, in Namazi et al. study, lowering the homocysteine concentration with folic acid therapy showed no significant effect on in-stent restenosis after PTCA. Our study suggested that elevated level of plasma tHcy was associated to an increased risk of CAD in Iranian population. A great advantage of our study was exclusion of patients with other confounding risk factors from our study, and then, this relationship seems to be independent of other CAD risk factors.

Conflict of Interests

Authors have no conflict of interests.

References

1. Smith SC. Current and future directions of cardiovascular risk prediction. Am J Cardiol 2006; 97(2A): 28A-32A.
2. Yan ZQ, Hansson GK. Innate immunity, macrophage activation, and atherosclerosis. Immunol Rev 2007; 219: 187-203.
3. Saadeddin SM, Habbab MA, Ferns GA. Markers of inflammation and coronary artery disease. Med Sci Monit 2002; 8(1): RAS-12.
4. Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J Lab Clin Med 1989; 114(5): 473-501.
5. Li JJ, Fang CH. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases. Med Hypotheses 2004; 62(4): 499-506.
6. Walld DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002; 325(7374): 1202.
7. Taylor LM, Jr., Moneta GL, Sexton GJ, Schuff RA, Porter JM. Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease. J Vasc Surg 1999; 29(1): 8-19.
8. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997; 277(22): 1775-81.
9. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324(17): 1149-55.
10. Genest JJ, McNamara JR, Salem DN, Wilson PW, Schaefer EJ, Malinow MR. Plasma homocyst(e)ine levels in men with premature coronary artery disease. J Am Coll Cardiol 1990; 16(5): 1114-9.
11. Robinson K, Mayer EL, Miller DP, Green R, van...
Lente F, Gupta A, et al. Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease. Circulation 1995; 92(10): 2825-30.

12. Sadeghian S, Fallahi F, Salarifar M, Davoodi G, Mahmoodian M, Fallah N, et al. Homocysteine, vitamin B12 and folate levels in premature coronary artery disease. BMC Cardiovasc Disord 2006; 6: 38.

13. Ceperkovic Z. The role of increased levels of homocysteine in the development of cardiovascular diseases. Med Pregl 2006; 59(3-4): 143-7.

14. Nygård O, Nordrehaug JE, Refsum H, Ueland PM, Forde AH, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337(4): 230-6.

15. Onat A, Hergenc G, Kucukdurmaz Z, Can G, Ayhan E, Bulur S. Serum folate is associated with coronary heart disease independently of homocysteine in Turkish men. Clin Nutr 2008; 27(5): 732-9.

16. Tokgozoglu SL, Aliskisfolgu M, Unsal, Atalar E, Aytemir K, Ozer N, et al. Methylenetetrahydrofolate reductase genotype and the risk and extent of coronary artery disease in a population with low plasma folate. Heart 1999; 81(5): 518-22.

17. Golbahar J, Rezaian GR. Association of Hyperhomocysteinemia with Coronary Artery Disease in Southern Iran. IJMS 2004; 29(3): 116.

18. Hajimoradi B, Bahrami GR, Kianz A, Kazerani H, Moloudi A, Rai A, et al. Homocysteine levels in patients with premature coronary artery disease. Hakim Research Journal 2007; 9(4): 31-6.

19. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274(13): 1049-57.

20. Arnese E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995; 24(4): 704-9.

21. Wald NJ, Watt HC, Law MR, Weir DG, McPartlin J, Scott JM. Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention. Arch Intern Med 1998; 158(8): 862-7.

22. Wilcken DE, Wang XL, Wilcken B. Methylenetetrahydrofolate reductase (MTHFR) mutation, homocyst(e)ine, and coronary artery disease. Circulation 1997; 96(8): 2738-40.

23. Brattstrom L. Common mutation in the methylenetetrahydrofolate reductase gene offers no support for mild hyperhomocysteinemia being a causal risk factor for cardiovascular disease. Circulation 1997; 96(10): 3805-7.

24. Donner MG, Klein GK, Mathes PB, Schwandt P, Richter WO. Plasma total homocysteine levels in patients with early-onset coronary heart disease and a low cardiovascular risk profile. Metabolism 1998; 47(3): 273-9.

25. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002; 288(16): 2015-22.

26. Evans RW, Shaten BJ, Hempel JD, Cutler JA, Kuller LH. Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscler Thromb Vasc Biol 1997; 17(10): 1947-53.

27. Alfihan G, Pekkanen J, Jauhiainen M, Pitkaniemi J, Karvonen M, Tuomilehto J, et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1994; 106(1): 9-19.

28. Welch GN, Losomalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998; 338(15): 1042-50.

29. Whincup PH, Refsum H, Perry IJ, Morris R, Walker M, Lennon L, et al. Serum total homocysteine and coronary heart disease: prospective study in middle aged men. Heart 1999; 82(4): 448-54.

30. Malinow MR, Bostom AG, Krauss RM. Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 1999; 99(1): 178-82.

31. Brattstrom L, Israelsson B, Lindgarde F, Hultberg B. Higher total plasma homocysteine in vitamin B12 deficiency than in heterozygosity for homocystinuria due to cystathionine beta-synthase deficiency. Metabolism 1988; 37(2): 175-8.

32. Daly L, Robinson K, Tan KS, Graham IM. Hyperhomocysteinemia: a metabolic risk factor for coronary heart disease determined by both genetic and environmental influences? Q J Med 1993; 86(10): 685-9.

33. Bailey LB, Gregory JF, III. Polymorphisms of methylenetetrahydrofolate reductase and other enzymes: metabolic significance, risks and impact on folate requirement. J Nutr 1999; 129(5): 919-22.

34. Fletcher O, Kessling AM. MTHFR association with arteriosclerotic vascular disease? Hum Genet 1998; 103(1): 11-21.

35. Franco RF, Araujo AG, Guerreiro JF, Elion J, Zago MA. Analysis of the 677 C–>T mutation of the methylenetetrahydrofolate reductase gene in different ethnic groups. Thromb Haemost 1998; 79(1): 119-21.

36. Schneider JA, Rees DC, Liu YT, Clegg JB. Worldwide distribution of a common methylenetetrahydrofolate reductase mutation. Am J Hum Genet 1998; 62(5): 1258-60.

37. Ou T, Yamakawa-Kobayashi K, Arinami T, Amemiya H, Fujiwara H, Kawata K, et al. Methylenetetrahydrofolate reductase and apolipoprotein E polymorphisms are independent risk factors for coronary artery disease. Circulation 1995; 92(10): 2825-30.
risk factors for coronary heart disease in Japanese: a case-control study. Atherosclerosis 1998; 137(1): 23-8.

38. Morita H, Kurihara H, Tsubaki S, Sugiyama T, Hamada C, Kurihara Y, et al. Methylene tetrahydrofolate reductase gene polymorphism and ischemic stroke in Japanese. Arterioscler Thromb Vasc Biol 1998; 18(9): 1465-9.

39. Izumi M, Iwai N, Ohmichi N, Nakamura Y, Shimoike H, Kinoshita M. Molecular variant of 5,10-methylenetetrahydrofolate reductase is a risk factor of ischemic heart disease in the Japanese population. Atherosclerosis 1996; 121(2): 293-4.

40. Kazemi MB, Eshraghian K, Omrani GR, Lankarani KB, Hosseini E. Homocysteine level and coronary artery disease. Angiology 2006; 57(1): 9-14.

41. Namazi MH, Motamedi MR, Safi M, Vakili H, Saadat H, Nazari N. Efficacy of folic acid therapy for prevention of in-stent restenosis: a randomized clinical trial. Arch Iran Med 2006; 9(2): 108-10.